Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2012 Dec 2:315–371. doi: 10.1016/B978-0-08-092599-8.50018-3

Vaccinia Virus Recombinants: Expression Vectors and Potential Vaccines

M MACKETT 1
Editors: RE SPIER2, JB GRIFFITHS3
PMCID: PMC7155698

The content is available as a PDF (6.8 MB).

REFERENCES

  • 1.Lifson J.D., Feinberg M.B., Reyes G.R., Rabin L., Banapour B., Chakrabarti S., Moss B., Wong S.F., Steimer K.S., Engleman E.G. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature. 1986;323:725–728. doi: 10.1038/323725a0. [DOI] [PubMed] [Google Scholar]
  • 2.Chakrabarti S., Mizukami T., Franchini G., Moss B. Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus. Virology. 1990;178:134–142. doi: 10.1016/0042-6822(90)90386-6. [DOI] [PubMed] [Google Scholar]
  • 3.Doms R.W., Earl P.L., Chakrabarti S., Moss B. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. J. Virol. 1990;64:3537–3540. doi: 10.1128/jvi.64.7.3537-3540.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chakrabarti S., Robert G.M., Wong S.F., Gallo R.C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 1986;320:535–537. doi: 10.1038/320535a0. [DOI] [PubMed] [Google Scholar]
  • 5.Hu S.L., Kosowski S.G., Dalrymple J.M. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature. 1986;320:537–540. doi: 10.1038/320537a0. [DOI] [PubMed] [Google Scholar]
  • 6.Earl P.L., Koenig S., Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 1991;65:31–41. doi: 10.1128/jvi.65.1.31-41.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cooney E.L., Collier A.C., Greenberg P.D., Coombs R.W., Zarling J., Arditti D.E., Hoffman M.C., Hu S.L., Corey L. Safety of and immunnological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991;337:567–572. doi: 10.1016/0140-6736(91)91636-9. [DOI] [PubMed] [Google Scholar]
  • 8.Cooney E.L., McElrath M.J., Corey L., Hu S.L., Collier A.C., Arditti D., Hoffman M., Coombs R.W., Smith G.E., Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. U.S.A. 1993;90(5):1882–1886. doi: 10.1073/pnas.90.5.1882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Graham B.S., Belshe R.B., Clements M.L., Dolin R., Corey L., Wright P.F., Gorse G.J., Midthun K., Keefer M.C., Roberts N.J. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 1992;166:244–252. doi: 10.1093/infdis/166.2.244. [DOI] [PubMed] [Google Scholar]
  • 10.Graham B.S., Matthews T.J., Belshe R.B., Clements M.L., Dolin R., Wright P.F., Gorse G.J., Schwartz D.H., Keefer M.C., Bolognesi D.P. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 1993;167:533–537. doi: 10.1093/infdis/167.3.533. [DOI] [PubMed] [Google Scholar]
  • 11.Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature. 1988;332:728–731. doi: 10.1038/332728a0. [DOI] [PubMed] [Google Scholar]
  • 12.Pincus S.H., Messer K.G., Schwartz D.H., Lewis G.K., Graham B.S., Blattner W.A., Fisher G. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest. 1993;91:1987–1996. doi: 10.1172/JCI116420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Van E.J., Yagello M., Girard M., Kieny M.P., Lecocq J.P., Muchmore E., Fultz P.N., Riviere Y., Montagnier L., Gluckman J.C. Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res. Hum. Retrovirus. 1989;5:41–50. doi: 10.1089/aid.1989.5.41. [DOI] [PubMed] [Google Scholar]
  • 14.Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghton R., Cornette J.L., DeLisi C., Moss B., Germain R.N., Berzofsky J.A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Pro. Natl. Acad. Sci. U.S.A. 1988;85:3105–3109. doi: 10.1073/pnas.85.9.3105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Polydefkis M., Koenig S., Flexner C., Obah E., Gebo K., Chakrabarti S., Earl P.L., Moss B., Siliciano R.F. Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4 + T cell recognition. J. Exp. Med. 1990;171:875–887. doi: 10.1084/jem.171.3.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Koup R.A., Robinson J.E., Nguyen Q.V., Pikora C.A., Blais B., Roskey A., Panicali D., Sullivan J.L. Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS. 1991;5:1309–1314. doi: 10.1097/00002030-199111000-00004. [DOI] [PubMed] [Google Scholar]
  • 17.Shepp D.H., Daguillard F., Mann D., Quinnan G.V. Human class I MHC-restricted cytotoxic T-lymphocytes specific for human immunodeficiency virus envelope antigens. AIDS. 1988;2:113–117. doi: 10.1097/00002030-198804000-00007. [DOI] [PubMed] [Google Scholar]
  • 18.Kieny M.P., Lathe R., Riviere Y., Dott K., Schmitt D., Girard M., Montagnier L., Lecocq J. Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng. 1988;2:219–225. doi: 10.1093/protein/2.3.219. [DOI] [PubMed] [Google Scholar]
  • 19.Fenouillet E., Jones I., Powell B., Schmitt D., Kieny M.P., Gluckman J.C. Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J. Virol. 1993;67:150–160. doi: 10.1128/jvi.67.1.150-160.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hallenberger S., Bosch V., Angliker H., Shaw E., Klenk H.D., Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature. 1992;360:358–361. doi: 10.1038/360358a0. [DOI] [PubMed] [Google Scholar]
  • 21.Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., Soulebot J.P., Desmettre P. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature. 1986;322:373–375. doi: 10.1038/322373a0. [DOI] [PubMed] [Google Scholar]
  • 22.Hanlon C.L., Hayes D.E., Hamir A.N., Snyder D.E., Jenkins S., Hable C.P., Rupprecht C.E. Proposed field evaluation of a rabies recombinant vaccine for raccoons (Procyon lotor): site selection, target species characteristics, and placebo baiting trials. J. Wildl. Dis. 1989;25:555–567. doi: 10.7589/0090-3558-25.4.555. [DOI] [PubMed] [Google Scholar]
  • 23.Tolson N.D., Charlton K.M., Stewart R.B., Campbell J.B., Wiktor T.J. Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can. J. Vet. Res. 1987;51:363–366. [PMC free article] [PubMed] [Google Scholar]
  • 24.Brochier B.M., Languet B., Artois M., Zanker S., Guittre C., Blancou J., Chappuis G., Desmettre P., Pastoret P.P. Efficacy of a baiting system for vaccinating foxes against rabies with vaccinia-rabies recombinant virus. Vet. Rec. 1990;127:165–167. [PubMed] [Google Scholar]
  • 25.Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre P., Afiademanyo K. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991;354:520–522. doi: 10.1038/354520a0. [DOI] [PubMed] [Google Scholar]
  • 26.Moss B. In: “Recombinant Poxviruses”. Binns M.M., Smith G.L., editors. CRC Press; Boca Raton, FL: 1992. pp. 45–80. [Google Scholar]
  • 27.Goebel S.J., Johnson G.P., Perkus M.E., Davis S.W., Winslow J.P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 1990;179:247–266. doi: 10.1016/0042-6822(90)90294-2. [DOI] [PubMed] [Google Scholar]
  • 28.Ahn B.Y., Moss B. RNA polymerase-associated transcription specificity factor encoded by vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 1992;89:3536–3540. doi: 10.1073/pnas.89.8.3536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Black M.E., Hruby D.E. A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase. J. Biol. Chem. 1992;267:9743–9748. [PubMed] [Google Scholar]
  • 30.McDonald W.F., Crozel G.V., Traktman P. Transient expression of the vaccinia virus DNA polymerase is an intrinsic feature of the early phase of infection and is unlinked to DNA replication and late gene expression. J. Virol. 1992;66:534–547. doi: 10.1128/jvi.66.1.534-547.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Stuart D.T., Upton C., Higman M.A., Niles E.G., McFadden G. A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. J. Virol. 1993;67:2503–2512. doi: 10.1128/jvi.67.5.2503-2512.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Alcami A., Smith G.L. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 1992;71:153–167. doi: 10.1016/0092-8674(92)90274-g. [DOI] [PubMed] [Google Scholar]
  • 33.Spriggs M.K., Hruby D.E., Maliszewski C.R., Pickup D.J., Sims J.E., Buller R.M., VanSlyke J. Vaccinia and cowpox viruses encode a novel secreted interleukin-1–binding protein. Cell. 1992;71:145–152. doi: 10.1016/0092-8674(92)90273-f. [DOI] [PubMed] [Google Scholar]
  • 34.Kotwal G., Moss B. Vaccinia encodes a secretory polypeptide structurally related to complement control proteins. Nature. 1988;335:176–178. doi: 10.1038/335176a0. [DOI] [PubMed] [Google Scholar]
  • 35.Kotwal G.J., Isaacs S.N., McKenzie R., Frank M.M., Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science. 1990;250:827–830. doi: 10.1126/science.2237434. [DOI] [PubMed] [Google Scholar]
  • 36.Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell Biol. 1985;5:3403–3409. doi: 10.1128/mcb.5.12.3403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Panicali D., Grzelecki A., Huang C. Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and mesurement of gene expression. Gene. 1986;47:193–199. doi: 10.1016/0378-1119(86)90063-6. [DOI] [PubMed] [Google Scholar]
  • 38.Boyle D.B., Coupar B.E. A dominant selectable marker for the construction of recombinant poxviruses. Gene. 1988;65:123–128. doi: 10.1016/0378-1119(88)90424-6. [DOI] [PubMed] [Google Scholar]
  • 39.Falkner F.G., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 1988;62:1849–1854. doi: 10.1128/jvi.62.6.1849-1854.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Franke C.A., Rice C.M., Strauss J.H., Hruby D.E. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Mol. Cell Biol. 1985;5:1918–1924. doi: 10.1128/mcb.5.8.1918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Perkus M.E., Limbach K., Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a hosts range selection system. J. Virol. 1989;63:3829–3836. doi: 10.1128/jvi.63.9.3829-3836.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zhou J., Crawford L., Sun X.Y., Frazer I.H. The hygromycin-resistance-encoding gene as a selection marker for vaccinia virus recombinants. Gene. 1991;107:307–312. doi: 10.1016/0378-1119(91)90331-5. [DOI] [PubMed] [Google Scholar]
  • 43.Rodriguez J.F., Esteban M. Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants. J. Virol. 1989;63:997–1003. doi: 10.1128/jvi.63.2.997-1001.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nakano E., Panicali D., Paoletti E. Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc. Natl. Acad. Sci. U.S.A. 1982;79:1593–1596. doi: 10.1073/pnas.79.5.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Panicali D., Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 1982;79(16):4927–4931. doi: 10.1073/pnas.79.16.4927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Flexner C., Hugin A., Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature. 1987;330:259–262. doi: 10.1038/330259a0. [DOI] [PubMed] [Google Scholar]
  • 47.Buller R.M., Chakrabarti S., Cooper J.A., Twardzik D.R., Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 1988;62:866–874. doi: 10.1128/jvi.62.3.866-874.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Binns M.M., Smith G.L., editors. “Recombinant Poxviruses”. CRC Press; Boca Raton, FL: 1992. [Google Scholar]
  • 49.Mackett M., Smith G.L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. U.S.A. 1982;79:7415–7419. doi: 10.1073/pnas.79.23.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 1984;49:857–864. doi: 10.1128/jvi.49.3.857-864.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Berthelot C., Drillien R., Wittek R. One hundred base pairs of 5′ flanking DNA are sufficient to temporally regulate late transcription. Proc. Natl. Acad. Sci. U.S.A. 1985;82:2096–2300. doi: 10.1073/pnas.82.7.2096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Stunnenberg H.G., Lange H., Philipson L., van M.R., van d.V.P. High expression of functional adenovirus DNA polymerase and precursor terminal protein using recombinant vaccinia virus. Nucleic Acids Res. 1988;16:2431–2444. doi: 10.1093/nar/16.6.2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Venkatesan S., Baroudy B.M., Moss B. Distinctive nucleotide sequences adjacent to mutiple initiation and termination sites of an early vaccinia virus gene. Cell. 1981;25:805–813. doi: 10.1016/0092-8674(81)90188-4. [DOI] [PubMed] [Google Scholar]
  • 54.Fuerst T.R., Earl P.L., Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol. Cell Biol. 1987;7:2538–2544. doi: 10.1128/mcb.7.7.2538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Elroy S.O., Fuerst T.R., Moss B. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5′ sequence improves the performance of the vaccinia virus/bacteriophace T7 hybrid expression system. Proc. Natl. Acad. Sci. U.S.A. 1989;86:6126–6130. doi: 10.1073/pnas.86.16.6126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Coupar B.E., Andrew M.E., Both G.W., Boyle D.B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 1986;16:1479–1487. doi: 10.1002/eji.1830161203. [DOI] [PubMed] [Google Scholar]
  • 57.Earl P.L., Hugin A.W., Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 1990;64:2448–2451. doi: 10.1128/jvi.64.5.2448-2451.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Spehner D., Drillien R., Lecocq J.P. Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene. J. Virol. 1990;64:527–533. doi: 10.1128/jvi.64.2.527-533.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Falkner F.G., Moss B. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 1990;64:3108–3111. doi: 10.1128/jvi.64.6.3108-3111.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Isaacs S.N., Kotwal G.J., Moss B. Reverse guanine phosphoribosyl-transferase selection of recombinant vaccinia viruses. Virology. 1990;178:626–630. doi: 10.1016/0042-6822(90)90367-z. [DOI] [PubMed] [Google Scholar]
  • 61.Fenner F., Woodruffe G.M. The reactivation of poxviruses II: the range of reactivating viruses. Virology. 1960;11:185–201. doi: 10.1016/0042-6822(60)90061-1. [DOI] [PubMed] [Google Scholar]
  • 62.Sam C-K., Dumbell K.R.D. Expression of poxvirus DNA in co-infected cells and marker rescue of thermosensitive mutants by sub-genomic fragments of DNA. Ann. Virol. (Inst. Pastuer) 1981;132E:135–150. [Google Scholar]
  • 63.Scheiflinger F., Dorner F., Falkner F.G. Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc. Natl. Acad. Sci. U.S.A. 1992;89:9977–9981. doi: 10.1073/pnas.89.21.9977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Falkner F., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 1988;62:1849–1854. doi: 10.1128/jvi.62.6.1849-1854.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Davison A.J., Moss B. Structure of vaccinia virus late promoters. J. Mol. Biol. 1989;210:771–784. doi: 10.1016/0022-2836(89)90108-3. [DOI] [PubMed] [Google Scholar]
  • 66.Davison A.J., Moss B. Structure of vaccinia virus early promoters. J. Mol. Biol. 1989;210:749–769. doi: 10.1016/0022-2836(89)90107-1. [DOI] [PubMed] [Google Scholar]
  • 67.Usdin T.B., Brownstein M.J., Moss B., Isaacs S.N. SP6 RNA polymerase containing vaccinia virus for rapid expression of cloned genes in tissue culture. Biotechniques. 1993;14:222–224. [PubMed] [Google Scholar]
  • 68.Rodriguez D., Zhou Y.W., Rodriguez J.R., Durbin R.K., Jimenez V., McAllister W.T., Esteban M. Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vectors. J. Virol. 1990;64:4851–4857. doi: 10.1128/jvi.64.10.4851-4857.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Barrett N., Mitterer A., Mundt W., Eibl J., Eibl M., Gallo R.C., Moss B., Dorner F. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retrovirus. 1989;5:159–171. doi: 10.1089/aid.1989.5.159. [DOI] [PubMed] [Google Scholar]
  • 70.Fuerst T.R., Moss B. Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cells: Importance of the 5′ untranslated leader. J. Mol. Biol. 1989;206:333–348. doi: 10.1016/0022-2836(89)90483-x. [DOI] [PubMed] [Google Scholar]
  • 71.Vennema H., Rijnbrand R., Heijnen L., Horzinek M.C., Spaan W.J. Enhancement of the vaccinia virus /phage T7 RNA polymerase expression system using encephalomyocarditis virus 5′-untranslated region sequences. Gene. 1991;108:201–209. doi: 10.1016/0378-1119(91)90435-E. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Rodriguez J.F., Smith G.L. Inducible gene expression from vaccinia virus vectors. Virology. 1990;177:239–250. doi: 10.1016/0042-6822(90)90477-9. [DOI] [PubMed] [Google Scholar]
  • 73.Rodriguez J.F., Smith G.L. IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress. Nucleic Acids Res. 1990;18:5347–5351. doi: 10.1093/nar/18.18.5347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Fuerst T.R., Fernandez M.P., Moss B. Transfer of the inducible lac repressor /operator system from Escherichia coli to a vaccinia virus expression vector. Proc. Natl. Acad. Sci. U.S.A. 1989;86:2549–2553. doi: 10.1073/pnas.86.8.2549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Kriajevska M.V., Zakharova L.G., Altstein A.D. Viable double vaccinia virus recombinants with the non-inducible phage T7 expression system. J. Gen. Virol. 1993;74:47–53. doi: 10.1099/0022-1317-74-1-47. [DOI] [PubMed] [Google Scholar]
  • 76.Alexander W.A., Moss B., Fuerst T.R. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J. Virol. 1992;66:2934–2942. doi: 10.1128/jvi.66.5.2934-2942.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Li Y., Luo L.Z., Snyder R.M., Wagner R.R. Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors. J. Virol. 1988;62:776–782. doi: 10.1128/jvi.62.3.776-782.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Berger E.A., Fuerst T.R., Moss B. A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 1988;85(7):2357–2361. doi: 10.1073/pnas.85.7.2357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Tifft C.J., Proia R.L., Camerini-Otero The folding and cell surface expression of CD4 requires glycosylation. J. Biol. Chem. 1992;267:3268–3273. [PubMed] [Google Scholar]
  • 80.Crise B., Rose J.K. Human immunodeficiency virus type 1 precursor retains a CD4–p56lck complex in the endoplasmic reticulum. J. Virol. 1992;66:2296–2301. doi: 10.1128/jvi.66.4.2296-2301.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Moss B., Elroy-Stein O., Mizukami T., Alexander W.A., Fuerst T.R. New mammalian expression vectors. Nature. 1990;348:91–92. doi: 10.1038/348091a0. [DOI] [PubMed] [Google Scholar]
  • 82.Rich D.P., Anderson M.P., Gregory R.J., Cheng S.H., Paul S., Jefferson D.M., McCann J.D., Klinger K.W., Smith A.E., Welsh M.J. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature. 1990;347:358–363. doi: 10.1038/347358a0. [DOI] [PubMed] [Google Scholar]
  • 83.Pattnaik A.K., Ball L.A., LeGrone A.W., Wertz G.W. Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell. 1992;69:1011–1020. doi: 10.1016/0092-8674(92)90619-n. [DOI] [PubMed] [Google Scholar]
  • 84.Falgout B., Miller R.H., Lai C.J. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 1993;67(4):2034–2042. doi: 10.1128/jvi.67.4.2034-2042.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Mackett M., Arrand J.R. Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 1985;4(12):3229–3234. doi: 10.1002/j.1460-2075.1985.tb04070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Leduc R., Molloy S.S., Thorne B.A., Thomas G. Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J. Biol. Chem. 1992;267:14304–14308. [PubMed] [Google Scholar]
  • 87.de l.S.H., Altenburger W., Elkaim R., Dott K., Dieterle A., Drillien R., Cazenave J.P., Tolstoshev P., Lecocq J.P. Active gamma-carboxylated human factor IX expressed using recombinant DNA techniques. Nature. 1985;316:268–270. doi: 10.1038/316268a0. [DOI] [PubMed] [Google Scholar]
  • 88.Guy B., Kieny M.P., Riviere Y., Le P.C., Dott K., Girard M., Montagnier L., Lecocq J.P. HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature. 1987;330:266–269. doi: 10.1038/330266a0. [DOI] [PubMed] [Google Scholar]
  • 89.Smith G.L., Godson G.N., Nussenzweig V., Nussenzweig R.S., Barnwell J., Moss B. Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. Science. 1984;224:397–399. doi: 10.1126/science.6200932. [DOI] [PubMed] [Google Scholar]
  • 90.Stephens E.B., Compans R.W., Earl P., Moss B. Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. EMBO J. 1986;5:237–245. doi: 10.1002/j.1460-2075.1986.tb04204.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Stephens E.B., Compans R.W. Nonpolarized expression of a secreted murine leukemia virus glycoprotein in polarized epithelial cells. Cell. 1986;47:1053–1059. doi: 10.1016/0092-8674(86)90820-2. [DOI] [PubMed] [Google Scholar]
  • 92.Bolmstedt A., Hemming A., Flodby P., Berntsson P., Travis B., Lin J.P., Ledbetter J., Tsu T., Wigzell H., Hu S.L., Olofosson S. Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4–binding and fusion activity of human immunodeficiency virus envelope glycoproteins. J. Gen. Virol. 1991;72:1269–1277. doi: 10.1099/0022-1317-72-6-1269. [DOI] [PubMed] [Google Scholar]
  • 93.Hutchinson L., Browne H., Wargent V., Davis P.N., Primorac S., Goldsmith K., Minson A.C., Johnson D.C. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J. Virol. 1992;66:2240–2250. doi: 10.1128/jvi.66.4.2240-2250.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Earl P.L., Moss B., Doms R.W. Folding, interaction with GRP78–BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 1991;65:2047–2055. doi: 10.1128/jvi.65.4.2047-2055.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Haffar O., Garrigues J., Travis B., Moran P., Zarling J., Hu S.L. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 1990;64:2653–2659. doi: 10.1128/jvi.64.6.2653-2659.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Ross E.K., Fuerst T.R., Orenstein J.M., O'Neill T., Martin M.A., Venkatesan S. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing, by gag-pol protease. AIDS Res. Hum. Retrovirus. 1991;7:475–483. doi: 10.1089/aid.1991.7.475. [DOI] [PubMed] [Google Scholar]
  • 97.Karacostas V., Wolffe E.J., Nagashima K., Gonda M.A., Moss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology. 1993;193:661–671. doi: 10.1006/viro.1993.1174. [DOI] [PubMed] [Google Scholar]
  • 98.Hoshikawa N., Kojima A., Yasuda A., Takayashiki E., Masuko S., Chiba J., Sata T., Kurata T. Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study. J. Gen. Virol. 1991;72:2509–2514. doi: 10.1099/0022-1317-72-10-2509. [DOI] [PubMed] [Google Scholar]
  • 99.Haffar O., Garrigues J., Travis B., Moran P., Zarling J., Hu S.L. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 1990;64:2653–2659. doi: 10.1128/jvi.64.6.2653-2659.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Voss G., Kirchhoff F., Nick S., Moosmayer D., Gelderblom H., Hunsmann G. Morphogenesis of recombinant HIV-2 gag core particles. Virus Res. 1992;24:197–210. doi: 10.1016/0168-1702(92)90007-v. [DOI] [PubMed] [Google Scholar]
  • 101.Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–257. doi: 10.1016/0042-6822(91)90772-4. [DOI] [PubMed] [Google Scholar]
  • 102.Hagensee M.E., Yaegashi N., Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 1993;67:315–322. doi: 10.1128/jvi.67.1.315-322.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Yang X.C., Karschin A., Labarca C., Elroy S.O., Moss B., Davidson N., Lester H.A. Expression of ion channels and receptors in Xenopus oocytes using vaccinia virus. Faseb J. 1991;5(8):2209–2216. doi: 10.1096/fasebj.5.8.1708738. [DOI] [PubMed] [Google Scholar]
  • 104.Leonard R.J., Karschin A., Jayashree A.S., Davidson N., Tanouye M.A., Thomas L., Thomas G., Lester H.A. Expression of Drosophila Shaker potassium channels in mammalian cells infected with recombinant vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 1989;86:7629–7633. doi: 10.1073/pnas.86.19.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Karschin A., Aiyar J., Gouin A., Davidson N., Lester H.A. K+ channel expression in primary cell cultures mediated by vaccinia virus. Febs Lett. 1991;278(2):229–233. doi: 10.1016/0014-5793(91)80123-k. [DOI] [PubMed] [Google Scholar]
  • 106.Karschin A., Ho B.Y., Labarca C., Elroy S.O., Moss B., Davidson N., Lester H.A. Heterologously expressed serotonin 1A receptors couple to muscarinic K+ channels in heart. Proc. Natl. Acad. Sci. U.S.A. 1991;88:5694–5698. doi: 10.1073/pnas.88.13.5694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.McQuade T.J., Tomasselli A.G., Liu L., Karacostas V., Moss B., Sawyer T.K., Heinrikson R.L., Tarpley W.G. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 1990;247:454–456. doi: 10.1126/science.2405486. [DOI] [PubMed] [Google Scholar]
  • 108.Yilma T., Ristow S.S., Moss B., Jones L. A novel approach for the production of monoclonal antibodies using infectious vaccinia virus recombinants. Hybridoma. 1987;6:329–335. doi: 10.1089/hyb.1987.6.329. [DOI] [PubMed] [Google Scholar]
  • 109.Brideau R.J., Walters R.R., Wathen M.W. Production, characterization, and utility of monoclonal antibodies which react with a novel chimeric glycoprotein of human respiratory syncytial virus termed FG. Hybridoma. 1989;8:623–629. doi: 10.1089/hyb.1989.8.623. [DOI] [PubMed] [Google Scholar]
  • 110.Malvoisin E., Wild F. Contribution of measles fusion protein in protective immunity: anti-F monoclonal antibodies neutralize infectivity and protect mice against challenge. J. Virol. 1990;64:5160–5166. doi: 10.1128/jvi.64.10.5160-5162.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Boyer V., Broly H., Souche S., Madaule P., Rossier J., Zagury D., Desgranges C. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope. Clin. Exp. Immunol. 1991;83:452–459. doi: 10.1111/j.1365-2249.1991.tb05660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.McClean C.S., Churcher M.J., Meinke J., Smith G.L., Higgins G., Stanley M., Minson A.C. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J. Clin. Pathol. 1990;43:488–491. doi: 10.1136/jcp.43.6.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Bennink J.R., Yewdell J.W. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Topics Microbiol. Immunol. 1990;163:153–184. doi: 10.1007/978-3-642-75605-4_6. [DOI] [PubMed] [Google Scholar]
  • 114.Gould K., Cossins J., Bastin J., Brownlee G.G., Townsend A. A 15 amino acid fragment of influenza nucleoprotein synthesized in the cytoplasm is presented to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 1989;170:1051–1056. doi: 10.1084/jem.170.3.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Smith G.L., Levin J.Z., Palese P., Moss B. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology. 1987;160:336–345. doi: 10.1016/0042-6822(87)90004-3. [DOI] [PubMed] [Google Scholar]; Smith G.L., Levin J.Z., Palese P., Moss B. Virology. 1988;163:259. doi: 10.1016/0042-6822(87)90004-3. [DOI] [PubMed] [Google Scholar]
  • 116.Bennink J.R., Yewdell J.W., Smith G.L., Moller C., Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 1984;311:578–579. doi: 10.1038/311578a0. [DOI] [PubMed] [Google Scholar]
  • 117.Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1985;82:1785–1789. doi: 10.1073/pnas.82.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Smith G.L. Vaccinia virus glycoproteins and immune evasion. J. Gen. Virol. 1993;74:1725–1740. doi: 10.1099/0022-1317-74-9-1725. [DOI] [PubMed] [Google Scholar]
  • 119.Voss G., Dittmer U., Coulibaly C., Makoschey B., Petry H., Luke W., Hunsmann G. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. J. Gen. Virol. 1993;74:1757–1763. doi: 10.1099/0022-1317-74-9-1757. [DOI] [PubMed] [Google Scholar]
  • 120.Gotch F., McMichael A., Smith G., Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 1987;165:408–416. doi: 10.1084/jem.165.2.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Bastin J.M., Townsend A.R., McMichael A.J. Specific recognition of influenza virus polymerase protein (PB1) by a murine cytotoxic T-cell clone. Virology. 1987;160:278–280. doi: 10.1016/0042-6822(87)90074-2. [DOI] [PubMed] [Google Scholar]
  • 122.Walker B.D., Flexner C., Birch L.K., Fisher L., Paradis T.J., Aldovini A., Young R., Moss B., Schooley R.T. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1989;86:9514–9518. doi: 10.1073/pnas.86.23.9514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Sutton J., Rowland J.S., Rosenberg W., Nixon D., Gotch F., Gao X.M., Murray N., Spoonas A., Driscoll P., Smith M. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur. J. Immunol. 1993;23:447–453. doi: 10.1002/eji.1830230222. [DOI] [PubMed] [Google Scholar]
  • 124.Walker B.D., Chakrabarti S., Moss B., Paradis T.J., Flynn T., Durno A.G., Blumberg R.S., Kaplan J.C., Hirsch M.S., Schooley R.T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987;328:345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  • 125.Walker B.D., Flexner C., Paradis T.J., Fuller T.C., Hirsch M.S., Schooley R.T., Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988;240:64–66. doi: 10.1126/science.2451288. [DOI] [PubMed] [Google Scholar]
  • 126.Nixon D.F., Townsend A.R., Elvin J.G., Rizza C.R., Gallwey J., McMichael A.J. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988;336:484–487. doi: 10.1038/336484a0. [DOI] [PubMed] [Google Scholar]
  • 127.Nixon D.F., Huet S., Rothbard J., Kieny M.P., Delchambre M., Thiriart C., Rizza C.R., Gotch F.M., McMichael A.J. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS. 1990;4:841–845. doi: 10.1097/00002030-199009000-00002. [DOI] [PubMed] [Google Scholar]
  • 128.Riviera Y., Tanneau S.F., Regnault A, Lopez O., Sansonetti P., Guy B., Kieny M.P., Fournel J.J., Montagnier L. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J. Virol. 1989;63:2270–2277. doi: 10.1128/jvi.63.5.2270-2277.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Buseyne F., McChesney M., Porrot F., Kovarik S., Guy B., Riviere Y. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J. Virol. 1993;67:694–702. doi: 10.1128/jvi.67.2.694-702.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Hany M., Oehen S., Schulz M., Hengartner H., Mackett M., Bishop D.H., Overton H., Zinkernagel R.M. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur. J. Immunol. 1989;19:417–424. doi: 10.1002/eji.1830190302. [DOI] [PubMed] [Google Scholar]
  • 131.Zagury D., Leonard R., Fouchard M., Reveil B., Bernard J., Ittele D., Cattan A., Zirimwabagabo L., Kalumbu M., Justin W. Immunization against AIDS in humans (letter) Nature. 1987;326:249–250. doi: 10.1038/326249a0. [DOI] [PubMed] [Google Scholar]
  • 132.Shepp D.H., Chakrabarti S., Moss B., Quinnan G.V., Jr. Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J. Inf. Dis. 1988;157:1260–1264. doi: 10.1093/infdis/157.6.1260. [DOI] [PubMed] [Google Scholar]
  • 133.Koup R.A., Pikora C.A., Mazzara G., Panicali D., Sullivan J.L. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol. 1991;4:215–223. doi: 10.1089/vim.1991.4.215. [DOI] [PubMed] [Google Scholar]
  • 134.Tanneau F., McChesney M., Lopez O., Sansonetti P., Montagnier L., Riviere Y. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity. in vivo. J. Infect. Dis. 1990;162:837–843. doi: 10.1093/infdis/162.4.837. [DOI] [PubMed] [Google Scholar]
  • 135.Barnett L.A., Whitton J.L., Wada Y., Fujinami R.S. Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J. Neuroimmunol. 1993;44:15–25. doi: 10.1016/0165-5728(93)90263-x. [DOI] [PubMed] [Google Scholar]
  • 136.Yoon J.W., Choi D.S., Liang H.C., Baek H.S., Ko I.Y., Jun H.S., Gillam S. Induction of an organ-specific autoimmune disease, lymphocytic hypophysitis, in hamsters by recombinant rubella virus glycoprotein and prevention of disease by neonatal thymectomy. J. Virol. 1992;66:1210–1214. doi: 10.1128/jvi.66.2.1210-1214.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Smith G.L., Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene. 1983;25:21–28. doi: 10.1016/0378-1119(83)90163-4. [DOI] [PubMed] [Google Scholar]
  • 138.Perkus M.E., Piccini A., Lipinskas B.R., Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985;229:981–984. doi: 10.1126/science.2992092. [DOI] [PubMed] [Google Scholar]
  • 139.Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968. National surveillance in the United States. N. Engl. J. Med. 1969;281:1201–1208. doi: 10.1056/NEJM196911272812201. [DOI] [PubMed] [Google Scholar]
  • 140.Redfield R.R., Wright D.C., James W.D., Jones T.S., Brown C., Burke D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 1987;316:673–676. doi: 10.1056/NEJM198703123161106. [DOI] [PubMed] [Google Scholar]
  • 141.Guillaume J.C., Saiag P., Wechsler J., Lescs M.C., Roujeau J.C. Vaccinia from recombinant virus expressing HIV genes. Lancet. 1991;337:1034–1035. doi: 10.1016/0140-6736(91)92689-y. [DOI] [PubMed] [Google Scholar]
  • 142.Picard O., Giral P., Defer M.C., Fouchard M., Morel M., Meyohas M.C., Lebas J., Imbert J.C., Frottier J., Salaun J.J., Lurhuma Z., Moss B., Gallo R.C., Zagury D. AIDS vaccine therapy: phase 1 trial. Lancet. 1990;336:179. doi: 10.1016/0140-6736(90)91699-b. [DOI] [PubMed] [Google Scholar]
  • 143.Flexner C., Murphy B.R., Rooney J.F., Wohlenberg C., Yuferov V., Notkins A.L., Moss B. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature. 1988;335(6187):259–262. doi: 10.1038/335259a0. [DOI] [PubMed] [Google Scholar]
  • 144.Rooney J.F., Wohlenberg C., Cremer K.J., Moss B., Notkins A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 1988;62:1530–1534. doi: 10.1128/jvi.62.5.1530-1534.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145.Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.-C., Cox W.I., Davis S.W., Van der Hoeven J., Meignier B., Riviere M., Languet B., Paoletti E. NYVAC: A highly attenuated strain of vaccinia virus. Virology. 1992;188:217–232. doi: 10.1016/0042-6822(92)90752-b. [DOI] [PubMed] [Google Scholar]
  • 146.Takahashi-Nishimaki F., Suzuki K., Morita M., Muruyama T., Miki K., Hasizume S., Sugimoto M. Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: Production of intermediate variants by homologous recombination. J. Gen. Virol. 1987;68:2705–2710. doi: 10.1099/0022-1317-68-10-2705. [DOI] [PubMed] [Google Scholar]
  • 147.Morita M., Suzuki K., Yasuda A., Kojima A., Sugimoto M., Watanabe K., Kobayashi H., Kajima K., Hashizume S. Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain. Vaccine. 1987;5:65–70. doi: 10.1016/0264-410x(87)90012-0. [DOI] [PubMed] [Google Scholar]
  • 148.Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991;72:1031–1038. doi: 10.1099/0022-1317-72-5-1031. [DOI] [PubMed] [Google Scholar]
  • 149.Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 1992;89:10847–10851. doi: 10.1073/pnas.89.22.10847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150.Buller R.M., Smith G.L., Cremer K., Notkins A.L., Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317(6040):813–815. doi: 10.1038/317813a0. [DOI] [PubMed] [Google Scholar]
  • 151.Rodriguez D., Rodriguez J.R., Rodriguez J.F., Trauber D., Esteban M. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc. Natl. Acad. Sci. U.S.A. 1989;86:1287–1291. doi: 10.1073/pnas.86.4.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Ruby J., Fordham S., Kasprzak A., Osvath S., Ramshaw I. The immunobiology of murine interleukin-1 alpha encoded by recombinant vaccinia virus. Cytokine. 1991;3:92–97. doi: 10.1016/1043-4666(91)90028-c. [DOI] [PubMed] [Google Scholar]
  • 153.Ramshaw I.A., Andrew M.E., Phillips S.M., Boyle D.B., Coupar B.E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 1987;329:545–546. doi: 10.1038/329545a0. [DOI] [PubMed] [Google Scholar]
  • 154.Andrew M.E., Karupiah G., Boyle D.B., Blanden R.V., Mullbacher A., Ramshaw I.A., Coupar B.E. Effects of vaccinia virus-expressed interleukin 2 on the immune system of sublethally irradiated mice. Microb. Pathol. 1991;10:363–371. doi: 10.1016/0882-4010(91)90081-k. [DOI] [PubMed] [Google Scholar]
  • 155.Mullbacher A., Ramshaw I.A., Coupar B.E. Vaccinia-interleukin 2 recombinant virus or exogenous interleukin 2 does not alter the magnitude or immune response gene defects of the cytotoxic T-cell response to vaccinia virus. in vivo. Scand. J. Immunol. 1989;29:1–6. doi: 10.1111/j.1365-3083.1989.tb01092.x. [DOI] [PubMed] [Google Scholar]
  • 156.Flexner C., Moss B., London W.T., Murphy B.R. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine. 1990;8:17–21. doi: 10.1016/0264-410x(90)90171-h. [DOI] [PubMed] [Google Scholar]
  • 157.Nakagawa N., Nakagawa T., Acres B., Yasukawa K., Kieny M.P. In vivo delivery of interleukin-6 using vaccinia virus: effects on T lymphocytes in nude mice. Eur. Cytokine Netw. 1991;2:11–16. [PubMed] [Google Scholar]
  • 158.Giavedoni L.D., Jones L., Gardner M.B., Gibson H.L., Ng C.T., Barr P.J., Yilma T. Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc. Natl. Acad. Sci. U.S.A. 1992;89:3409–3413. doi: 10.1073/pnas.89.8.3409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Langford C.J., Edwards S.J., Smith G.L., Mitchell G.F., Moss B., Kemp D.J., Anders R.F. Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity. Mol. Cell Biol. 1986;6:3191–3199. doi: 10.1128/mcb.6.9.3191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Zhou J., Crawford L., McLean L., Sun X.Y., Stanley M., Almond N., Smith G.L. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J. Gen. Virol. 1990;71:2185–2190. doi: 10.1099/0022-1317-71-9-2185. [DOI] [PubMed] [Google Scholar]
  • 161.Kotwal G.J., Hugin A.W., Moss B. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology. 1989;171:579–587. doi: 10.1016/0042-6822(89)90627-2. [DOI] [PubMed] [Google Scholar]
  • 162.Huang C., Samsonoff W.A., Grzelecki A. Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles. J. Virol. 1988;62:3855–3861. doi: 10.1128/jvi.62.10.3855-3861.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Rodriguez J.R., Rodriguez D., Esteban M. Structural properties of HIV-1 Env fused with the 14-kDa vaccinia virus envelope protein. Virology. 1991;181:742–748. doi: 10.1016/0042-6822(91)90910-4. [DOI] [PubMed] [Google Scholar]
  • 164.Picard O., Achour A., Bernard J., Halbreich A., Bizzini B., Boyer V., Desgranges C., Bertho J.M., Lachgar A., Polliotti B. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160–immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J. Acquired Immune Def. Synd. 1992;5:539–546. [PubMed] [Google Scholar]
  • 165.Hu S.L., Klaniecki J., Dykers T., Sridhar P., Travis B.M. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res. Hum. Retrovirus. 1991;7:615–620. doi: 10.1089/aid.1991.7.615. [DOI] [PubMed] [Google Scholar]
  • 166.Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992;339:1429–1432. doi: 10.1016/0140-6736(92)92027-d. [DOI] [PubMed] [Google Scholar]
  • 167.Yilma T., Hsu D., Jones L., Owens S., Grubman M., Mebus C., Yamanaka M., Dale B. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science. 1988;242:1058–1061. doi: 10.1126/science.3194758. [DOI] [PubMed] [Google Scholar]
  • 168.Barrett T., Belsham G.J., Subbarao S.M., Evans S.A. Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus. Virology. 1989;170:11–18. doi: 10.1016/0042-6822(89)90346-2. [DOI] [PubMed] [Google Scholar]
  • 169.Belsham G.J., Anderson E.C., Murray P.K., Anderson J., Barrett T. Immune response and protection of cattle and pigs generated by a vaccinia virus recombinant expressing the F protein of rinderpest virus. Vet. Rec. 1989;124:655–658. doi: 10.1136/vr.124.25.655. [DOI] [PubMed] [Google Scholar]
  • 170.Yamanouchi K., Inui K., Sugimoto M., Asano K., Nishimaki F., Kitching R.P., Takamatsu H., Barrett T. Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus. Vet. Rec. 1993;132:152–156. doi: 10.1136/vr.132.7.152. [DOI] [PubMed] [Google Scholar]
  • 171.Esposito J.J., Knight J.C., Shaddock J.H., Novembre F.J., Baer G.M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 1988;165:313–316. doi: 10.1016/0042-6822(88)90692-7. [DOI] [PubMed] [Google Scholar]
  • 172.Baylor N.W., Li Y., Ye Z.P., Wagner R.R. Transient expression and sequence of the matrix (M1) gene of WSN influenza A virus in a vaccinia vector. Virology. 1988;163(2):618–621. doi: 10.1016/0042-6822(88)90303-0. [DOI] [PubMed] [Google Scholar]
  • 173.Andreasson K.I., Tarn W.W., Feurst T.O., Moss B., Loh Y.P. Production of pro-opiomelanocortin (POMC) by a vaccinia virus transient expression system and in vitro processing of the expressed prohormone by POMC-converting enzyme. Febs. Lett. 1989;248(1–2):43–47. doi: 10.1016/0014-5793(89)80428-4. [DOI] [PubMed] [Google Scholar]
  • 174.Frattali A.L., Pessin J.E. Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J. Biol. Chem. 1993;268(10):7393–7400. [PubMed] [Google Scholar]
  • 175.Yao Z., Jackson W., Forghani B., Grose C. Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J. Virol. 1993;67(1):305–314. doi: 10.1128/jvi.67.1.305-314.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 1993;67(3):1385–1395. doi: 10.1128/jvi.67.3.1385-1395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Jin H., Elliott R.M. Mutagenesis of the L protein encoded by Bunyamwera virus and production of monospecific antibodies. J. Gen. Virol. 1992;73:2235–2244. doi: 10.1099/0022-1317-73-9-2235. [DOI] [PubMed] [Google Scholar]
  • 178.Keynan S., Suh Y.J., Kanner B.I., Rudnick G. Expression of a cloned gamma-aminobutyric acid transporter in mammalian cells. Biochemistry. 1992;31(7):1974–1979. doi: 10.1021/bi00122a011. [DOI] [PubMed] [Google Scholar]
  • 179.Lemm J.A., Rice C.M. Assembly of functional Sindbis virus RNA replication complexes: requirement for coexpression of P123 and P34. J. Virol. 1993;67(4):1905–1915. doi: 10.1128/jvi.67.4.1905-1915.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180.Perez L.G., O'Donnell M.A., Stephens E.B. The transmembrane glycoprotein of human immunodeficiency virus type 1 induces syncytium formation in the absence of the receptor binding glycoprotein. J. Virol. 1992;66(7):4134–4143. doi: 10.1128/jvi.66.7.4134-4143.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Pfleiderer M., Routledge E., Herder G., Siddell S.G. High level transient expression of the murine coronavirus haemagglutinin-esterase. J. Gen. Virol. 1991;72:1309–1315. doi: 10.1099/0022-1317-72-6-1309. [DOI] [PubMed] [Google Scholar]
  • 182.Hu, X., Ray, R., and Compans, R. W. Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J. Virol.66, 1528–1534. [DOI] [PMC free article] [PubMed]
  • 183.Cantin E.M., Eberle R., Baldick J.L., Moss B., Willey D.E., Notkins A.L., Openshaw H. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc. Natl. Acad. Sci. U.S.A. 1987;84:5908–5912. doi: 10.1073/pnas.84.16.5908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Martin S., Cantin E., Rouse B.T. Cytotoxic T lymphocytes. Their relevance in herpesvirus infections. Ann. N.Y. Acad. Sci. 1988;532(257):257–272. doi: 10.1111/j.1749-6632.1988.tb36344.x. [DOI] [PubMed] [Google Scholar]
  • 185.Martin S., Cantin E., Rouse B.T. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoprotein. J. Gen. Virol. 1989;70:1359–1370. doi: 10.1099/0022-1317-70-6-1359. [DOI] [PubMed] [Google Scholar]
  • 186.McLaughlin T.E., Willey D.E., Cantin E.M., Eberle R., Moss B., Openshaw H. A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice. J. Gen. Virol. 1988;69:1731–1734. doi: 10.1099/0022-1317-69-7-1731. [DOI] [PubMed] [Google Scholar]
  • 187.Willey D.E., Cantin E.M., Hill L.R., Moss B., Notkins A.L., Openshaw H. Herpes simplex virus type 1–vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection. J. Infect. Dis. 1988;158(6):1382–1386. doi: 10.1093/infdis/158.6.1382. [DOI] [PubMed] [Google Scholar]
  • 188.Weir J.P., Bennett M., Allen E.M., Elkins K.L., Martin S., Rouse B.T. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J. Gen. Virol. 1989 doi: 10.1099/0022-1317-70-10-2587. [DOI] [PubMed] [Google Scholar]
  • 189.Allen E.M., Weir J.P., Martin S., Mercadal C., Rouse B.T. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity. Viral Immunol. 1990;3(3):207–215. doi: 10.1089/vim.1990.3.207. [DOI] [PubMed] [Google Scholar]
  • 190.Martin S., Mercadal C.M., Weir J.P., Rouse B.T. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization. Viral Immunol. 1993;6(1):21–33. doi: 10.1089/vim.1993.6.21. [DOI] [PubMed] [Google Scholar]
  • 191.Cremer K.J., Mackett M., Wohlenberg C., Notkins A.L., Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 1985;228(4700):737–740. doi: 10.1126/science.2986288. [DOI] [PubMed] [Google Scholar]
  • 192.Martin S., Rouse B.T. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. J. Immunol. 1987;138(10):3431–3437. [PubMed] [Google Scholar]
  • 193.Wachsman M., Aurelian L., Smith C.C., Perkus M.E., Paoletti E. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease. J. Infect. Dis. 1989;159(4):625–634. doi: 10.1093/infdis/159.4.625. [DOI] [PubMed] [Google Scholar]
  • 194.Nesburn A.B., Ghiasi H., Wechsler S.L. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest Ophthalmol. Vis. Sci. 1990;31(8):1497–1502. [PubMed] [Google Scholar]
  • 195.Gillespie J.H., Geissinger C., Scott F.W., Higgins W.P., Holmes D.F., Perkus M., Mercer S., Paoletti E. Response of dairy calves to vaccinia viruses that express foreign genes. J. Clin. Microbiol. 1986;23(2):283–288. doi: 10.1128/jcm.23.2.283-288.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196.Bell S., Cranage M., Borysiewicz L., Minson T. Induction of immunoglobulin G Fe receptors by recombinant vaccinia viruses expressing glycoproteins E and I of herpes simplex virus type 1. J. Virol. 1990;64(5):2181–2186. doi: 10.1128/jvi.64.5.2181-2186.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 197.Sullivan V., Smith G.L. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody. J. Gen. Virol. 1987;(5) doi: 10.1099/0022-1317-68-10-2587. [DOI] [PubMed] [Google Scholar]
  • 198.Forrester A.J., Sullivan V., Simmons A., Blacklaws B.A., Smith G.L., Nash A.A., Minson A.C. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus. J. Gen. Virol. 1991;72:369–375. doi: 10.1099/0022-1317-72-2-369. [DOI] [PubMed] [Google Scholar]
  • 199.Stunnenberg H.G., Lange H., Philipson L., van Miltenburg R.T., van der Vliet P.C. High expression of functional adenovirus DNA polymerase and precursor terminal protein using recombinant vaccinia virus. Nucleic Acids Res. 1988;16:2431–2444. doi: 10.1093/nar/16.6.2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200.Sullivan V., Smith G.L. The herpes simplex virus type 1 US7 gene product is a 66 K glycoprotein and is a target for complement-dependent virus neutralization. J. Gen. Virol. 1988;69:859–867. doi: 10.1099/0022-1317-69-4-859. [DOI] [PubMed] [Google Scholar]
  • 201.Zhu X.X., Papavassiliou A.G., Stunnenburg H.G., Silverstein S. Transactivation by herpes simplex virus proteins ICP4 and ICP0 in vaccinia virus infected cells. Virology. 1991;184(1):67–78. doi: 10.1016/0042-6822(91)90822-s. [DOI] [PubMed] [Google Scholar]
  • 202.Martin S., Zhu X.X., Silverstein S.J., Courtney R.J., Yao F., Jenkins F.J., Rouse B.T. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0. J. Gen. Virol. 1990;71:2391–2399. doi: 10.1099/0022-1317-71-10-2391. [DOI] [PubMed] [Google Scholar]
  • 203.Banks T.A., Nair S., Rouse B.T. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. J. Virol. 1993;67(1):613–616. doi: 10.1128/jvi.67.1.613-616.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204.Coupar B.E., Andrew M.E., Boyle D.B. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene. 1988;68(1):1–10. doi: 10.1016/0378-1119(88)90593-8. [DOI] [PubMed] [Google Scholar]
  • 205.Sharif A., Mars M., Dru A., Beaud G. Expression of herpes simplex virus thymidine kinase, mediated by vaccinia virus early promoters. Res. Virol. 1989;140(2):103–113. doi: 10.1016/s0923-2516(89)80088-3. [DOI] [PubMed] [Google Scholar]
  • 206.Coupar B.E., Boyle D.B., Both G.W. Effect of in vitro mutations in a vaccinia virus early promoter region monitored by herpes simplex virus thymidine kinase expression in recombinant vaccinia virus. J. Gen. Virol. 1987 doi: 10.1099/0022-1317-68-9-2299. [DOI] [PubMed] [Google Scholar]
  • 207.Tigges M.A., Koelle D., Hartog K., Sekulovich R.L., Corey L., Burke R.L. Human CD8 + herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J. Virol. 1992;66(3):1622–1634. doi: 10.1128/jvi.66.3.1622-1634.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 208.van v. d. H. S.D.L., Zamb T., Babiuk L.A. Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virus. J. Virol. 1989;63(5):2159–2168. doi: 10.1128/jvi.63.5.2159-2168.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 209.van v. d. H. S. D.L., Parker M.D., Massie B., van d.H.J., Harland R., Babiuk L.A., Zamb T.J. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV. Vaccine. 1993;11(1):25–35. doi: 10.1016/0264-410x(93)90336-v. [DOI] [PubMed] [Google Scholar]
  • 210.Tikoo S.K., Zamb T.J., Babiuk L.A. Analysis of bovine herpesvirus 1 glycoprotein gIV truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 1993;67(4):2103–2109. doi: 10.1128/jvi.67.4.2103-2109.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211.Tikoo S.K., Parker M.D., van d.H.J., Kowalski J., Zamb T.J., Babiuk L.A. Role of N-linked glycans in antigenicity, processing, and cell surface expression of bovine herpesvirus 1 glycoprotein gIV. J. Virol. 1993;67(2):726–733. doi: 10.1128/jvi.67.2.726-733.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212.Bell C.W., Boyle D.B., Whalley J.M. Transcript analysis of the equine herpesvirus 1 glycoprotein B gene homologue and its expression by a recombinant vaccinia virus. J. Gen. Virol. 1990;71:1119–1129. doi: 10.1099/0022-1317-71-5-1119. [DOI] [PubMed] [Google Scholar]
  • 213.Guo P.X., Goebel S., Davis S., Perkus M.E., Languet B., Desmettre P., Allen G., Paoletti E. Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J. Virol. 1989;63(10):4189–4198. doi: 10.1128/jvi.63.10.4189-4198.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214.Guo P.X., Goebel S., Perkus M.E., Taylor J., Norton E., Allen G., Languet B., Desmettre P., Paoletti E. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity. J. Virol. 1990;64(5):2399–2406. doi: 10.1128/jvi.64.5.2399-2406.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 215.Marchioli C.C., Yancey R.J., Petrovskis E.A., Timmins J.G., Post L.E. Evaluation of Pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. J. Virol. 1987;61(12):3977–3982. doi: 10.1128/jvi.61.12.3977-3982.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216.Kost T.A., Jones E.V., Smith K.M., Reed A.P., Brown A.L., Miller T.J. Biological evaluation of glycoproteins mapping to two distinct mRNAs within the BamHI fragment 7 of Pseudorabies virus: expression of the coding regions by vaccinia virus. Virology. 1989;171(2):365–376. doi: 10.1016/0042-6822(89)90604-1. [DOI] [PubMed] [Google Scholar]
  • 217.Riviere M., Tartaglia J., Perkus M.E., Norton E.K., Bongermino C.M., Lacoste F., Duret C., Desmettre P., Paoletti E. Protection of mice and swine from Pseudorabies virus conferred by vaccinia virus-based recombinants. J. Virol. 1992;66(6):3424–3434. doi: 10.1128/jvi.66.6.3424-3434.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Koszinowski U.H., Reddehase M.J., Keil G.M., Volkmer H., Jonjic S., Messerle M., del V.M., Mutter W., Munch K., Buhler B. Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol. Lett. 1987;16(3–4):185–192. doi: 10.1016/0165-2478(87)90146-5. [DOI] [PubMed] [Google Scholar]
  • 219.Volkmer H., Bertholet C., Jonjic S., Wittek R., Koszinowski U.H. Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp 89 expressed by recombinant vaccinia virus. J. Exp. Med. 1987;166(3):668–677. doi: 10.1084/jem.166.3.668. [DOI] [PMC free article] [PubMed] [Google Scholar]; Volkmer H., Bertholet C., Jonjic S., Wittek R., Koszinowski U.H. J. Exp. Med. 1987;166:1608. doi: 10.1084/jem.166.3.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Rapp M., Messerle M., Buhler B., Tannheimer M., Keil G.M., Koszinowski U.H. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol. 1992;66(7):4399–4406. doi: 10.1128/jvi.66.7.4399-4406.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Morgan A.J., Mackett M., Finerty S., Arrand J.R., Scullion F.T., Epstein M.A. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J. Med. Virol. 1988;25(2):189–195. doi: 10.1002/jmv.1890250209. [DOI] [PubMed] [Google Scholar]
  • 222.Mackett M., Conway M.J., Arrand J.R., Haddad R.S., Hutt F.L. Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment. J. Virol. 1990;64(6):2545–2552. doi: 10.1128/jvi.64.6.2545-2552.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223.Lear A.L., Rowe M., Kurilla M.G., Lee S., Henderson S., Kieff E., Rickinson A.B. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J. Virol. 1992;66(12):7461–7468. doi: 10.1128/jvi.66.12.7461-7468.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224.Murray R.J., Kurilla M.G., Brooks J.M., Thomas W.A., Rowe M., Kieff E., Rickinson A.B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 1992;176(1):157–168. doi: 10.1084/jem.176.1.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 225.Gavioli R., Kurilia M.G., de C.L.P., Wallace L.E., Dolcetti R., Murray R.J., Rickinson A.B., Masucci M.G. Multiple HLA All-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J. Virol. 1993;67(3):1572–1578. doi: 10.1128/jvi.67.3.1572-1578.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 226.Kinchington P.R., Hougland J.K., Arvin A.M., Ruyechan W.T., Hay J. The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J. Virol. 1992;66(1):359–366. doi: 10.1128/jvi.66.1.359-366.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 227.Arvin A.M., Sharp M., Smith S., Koropchak C.M., Diaz P.S., Kinchington P., Ruyechan W., Hay J. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J. Immunol. 1991;146(1):257–264. [PubMed] [Google Scholar]
  • 228.Lowry P.W., Solem S., Watson B.N., Koropchak C.M., Thackray H.M., Kinchington P.R., Ruyechan W.T., Ling P., Hay J., Arvin A.M. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. J. Gen. Virol. 1992;73:811–819. doi: 10.1099/0022-1317-73-4-811. [DOI] [PubMed] [Google Scholar]
  • 229.Stevenson D., Colman K.L., Davison A.J. Characterization of the varicella-zoster virus gene 61 protein. J. Gen. Virol. 1992;73:521–530. doi: 10.1099/0022-1317-73-3-521. [DOI] [PubMed] [Google Scholar]
  • 230.Borysiewicz L.K., Hickling J.K., Graham S., Sinclair J., Cranage M.P., Smith G.L., Sissons J.G. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 1988;168(3):919–931. doi: 10.1084/jem.168.3.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231.Cranage M.P., Kouzarides T., Bankier A.T., Satchwell S., Weston K., Tomlinson P., Barrell B., Hart H., Bell S.E., Minson A.C. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J. 1986;5(11):3057–3063. doi: 10.1002/j.1460-2075.1986.tb04606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 232.Cranage M.P., Smith G.L., Bell S.E., Hart H., Brown C., Bankier A.T., Tomlinson P., Barrell B.G., Minson T.C. Identificafion and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H. J. Virol. 1988;62(4):1416–1422. doi: 10.1128/jvi.62.4.1416-1422.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 233.Kaye J.F., Gompels U.A., Minson A.C. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product. J. Gen. Virol. 1992;73:2693–2698. doi: 10.1099/0022-1317-73-10-2693. [DOI] [PubMed] [Google Scholar]
  • 234.Liu D.X., Gompels U.A., Nicholas J., Lelliot C. Identification and expression of the human herpesvirus 6 glycoprotein H and interaction with an accessory 40 K glycoprotein. J. Gen. Virol. 1993;74:1847–1857. doi: 10.1099/0022-1317-74-9-1847. [DOI] [PubMed] [Google Scholar]
  • 235.Lindberg I., Thomas G. Cleavage of proenkephalin by a chromaffin granule processing enzyme. Endocrinology. 1990;126:480–487. doi: 10.1210/endo-126-1-480. [DOI] [PubMed] [Google Scholar]
  • 236.Smeekens S.P., Montag A.G., Thomas G., Albiges R.C., Carroll R., Benig M., Phillips L.A., Martin S., Ohagi S., Gardner P. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc. Natl. Acad. Sci. U.S.A. 1992;89:8822–8826. doi: 10.1073/pnas.89.18.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237.Falkner F.G., Turecek P.L., MacGillivray R.T., Bodemer W., Scheiflinger F., Kandels S., Mitterer A., Kistner O., Barrett N., Eibl J. High level expression of active human prothrombin in a vaccinia virus expression system. Thromb. Haemost. 1992;68:119–124. [PubMed] [Google Scholar]
  • 238.Zibert A., Selinka H.C., Elroy S.O., Moss B., Wimmer E. Vaccinia virus-mediated expression and identification of the human poliovirus receptor. Virology. 1991;182:250–259. doi: 10.1016/0042-6822(91)90668-2. [DOI] [PubMed] [Google Scholar]
  • 239.Edwards R.H., Selby M.J., Garcia P.D., Rutter W.J. Processing of the native nerve growth factor precursor to form biologically active nerve growth factor. J. Biol. Chem. 1988;263:6810–6815. [PubMed] [Google Scholar]
  • 240.Gotz R., Raulf F., Schartl M. Brain-derived neurotrophic factor is more highly conserved in structure and function than nerve growth factor during vertebrate evolution. J. Neurochem. 1992;59:432–442. doi: 10.1111/j.1471-4159.1992.tb09389.x. [DOI] [PubMed] [Google Scholar]
  • 241.Wetmore C.J., Cao Y., Pettersson R.F., Olson L. Brain-derived neurotrophic factor (BDNF) peptide antibodies: characterization using a Vaccinia virus expression system. J. Histochem. Cytochem. 1993;41:521–533. doi: 10.1177/41.4.8450192. [DOI] [PubMed] [Google Scholar]
  • 242.Verrijzer C.P., Kal A.J., Van d.V.P. The DNA binding domain (POU domain) of transcription factor oct-1 suffices for stimulation of DNA replication. EMBO J. 1990;9:1883–1888. doi: 10.1002/j.1460-2075.1990.tb08314.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 243.Verrijzer C.P., van O.J., van d.V.P. The Oct-1 POU domain mediates interactions between Oct-1 and other POU proteins. Mol. Cell. Biol. 1992;12:542–551. doi: 10.1128/mcb.12.2.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 244.Coupar B.E., Andrew M.E., Boyle B., Blanden R.V. Immune responses to H-2Kd antigen expressed by recombinant vaccinia vinis. Proc. Natl. Acad. Sci. U.S.A. 1986;83:7879–7882. doi: 10.1073/pnas.83.20.7879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 245.Ronen D., Teitz Y., Goldfinger N., Rotter V. Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses. Nucleic Acids Res. 1992;20:3435–3441. doi: 10.1093/nar/20.13.3435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 246.Tisdale E.J., Bourne J.R., Khosravi F.R., Der C.J., Balch W.E. GTP-binding mutants of rab1 and rab2 are potent inhibitors of vesicular transport from the endoplasmic reticulum to the Golgi complex. J. Cell Biol. 1992;119:749–761. doi: 10.1083/jcb.119.4.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 247.Templeton D.J. Nuclear binding of purified retinoblastoma gene product is determined by cell cycle-regulated phosphorylation. Mol. Cell Biol. 1992;12:435–443. doi: 10.1128/mcb.12.2.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 248.Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 1992;84:1084–1091. doi: 10.1093/jnci/84.14.1084. [DOI] [PubMed] [Google Scholar]
  • 249.Cao Y., Ekstrom M., Pettersson R.F. Characterization of the nuclear translocation of acidic fibroblast growth factor. J. Cell Sci. 1993;104:77–87. doi: 10.1242/jcs.104.1.77. [DOI] [PubMed] [Google Scholar]
  • 250.Reddy A.P., Chen J.Y., Zacharewski T., Gronemeyer H., Voorhees J.J., Fisher G.J. Characterization and purification of human retinoic acid receptor-gamma 1 overexpressed in the baculovirus-insect cell system. Biochem J. 1992;287:833–840. doi: 10.1042/bj2870833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 251.Aoyama T., Yamano S., Guzelian P.S., Gelboin H.V., Gonzalez F.J. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 1990;87:4790–4793. doi: 10.1073/pnas.87.12.4790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 252.Aoyama T., Nagata K., Yamazoe Y., Kato R., Matsunaga E., Gelboin H.V., Gonzalez F.J. Cytochrome b5 potentiation of cytochrome P-450 catalytic activity demonstrated by a vaccinia virus-mediated in situ reconstitution system. Proc. Natl. Acad. Sci. U.S.A. 1990;87:5425–5429. doi: 10.1073/pnas.87.14.5425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 253.Griffin H., Rowe M., Murray R., Brooks J., Rickinson A. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. Eur. J. Immunol. 1992;22:1741–1748. doi: 10.1002/eji.1830220712. [DOI] [PubMed] [Google Scholar]
  • 254.Karupiah G., Coupar B.E., Andrew M.E., Boyle D.B., Phillips S.M., Mullbacher A., Blanden R.V., Ramshaw I.A. Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J. Immunol. 1990;144:290–298. [PubMed] [Google Scholar]
  • 255.Corcoran L.M., Metcalf D., Edwards J., Handman E. GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous leishmaniasis. J. Parasitol. 1988;74:763–767. [PubMed] [Google Scholar]
  • 256.Lall L., Srinivasan J., Rao L.V., Jain S.K., Talwar G.P., Chakrabarti S. Recombinant vaccinia virus expresses immunoreactive alpha subunit of ovine luteinizing hormone which associates with beta-hCG to generate bioactive dimer. Ind. J. Biochem. Biophys. 1988;25:510–514. [PubMed] [Google Scholar]
  • 257.Chakrabarti S., Srinivasan J., Lall L., Rao L.V., Talwar G.P. Expression of biologically active human chorionic gonadotropin and its subunits by recombinant vaccinia virus. Gene. 1989;77:87–93. doi: 10.1016/0378-1119(89)90362-4. [DOI] [PubMed] [Google Scholar]
  • 258.Hogervorst E.J., Schouls L., Wagenaar J.P., Boog C.J., Spaan W.J., van E.J., van E.W. Modulation of experimental autoimmunity: treatment of adjuvant arthritis by immunization with a recombinant vaccinia virus. Infect. Immunol. 1991;59:2029–2035. doi: 10.1128/iai.59.6.2029-2035.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 259.Beebe S.J., Leyton L., Burks D., Ishikawa M., Fuerst T., Dean J., Saling P. Recombinant mouse ZP3 inhibits sperm binding and induces the acrosome reaction. Dev. Biol. 1992;151:48–54. doi: 10.1016/0012-1606(92)90212-y. [DOI] [PubMed] [Google Scholar]
  • 260.Hruby D.E., Hodges W.M., Wilson E.M., Franke C.A., Fischetti V.A. Expression of streptococcal M protein in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1988;85:5714–5717. doi: 10.1073/pnas.85.15.5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 261.Fischettti V.A., Hodges W.M., Hruby D.E. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science. 1989;244:1487–1490. doi: 10.1126/science.2660266. [DOI] [PubMed] [Google Scholar]
  • 262.Werenskiold A.K. Characterization of a secreted glycoprotein of the immunoglobulin superfamily inducible by mitogen and oncogene. Eur. J. Biochem. 1992;204:1041–1047. doi: 10.1111/j.1432-1033.1992.tb16726.x. [DOI] [PubMed] [Google Scholar]
  • 263.Schneider S.J., von B.A., Schachner M. Recombinant peripheral myelin protein Po confers both adhesion and neurite outgrowth-promoting properties. J. Neurosci. Res. 1990;27:286–297. doi: 10.1002/jnr.490270307. [DOI] [PubMed] [Google Scholar]
  • 264.Pye D., Edwards S.J., Anders R.F., O'Brien C.M., Franchina P., Corcoran L.N., Monger C., Peterson M.G., Vandenberg K.L., Smythe J.A. Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. Infect. Immun. 1991;59:2403–2411. doi: 10.1128/iai.59.7.2403-2411.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 265.Satchidanandam V., Zavala F., Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of. Plasmodium bergbei. Mol. Biochem. Parasitol. 1991;48:89–99. doi: 10.1016/0166-6851(91)90167-5. [DOI] [PubMed] [Google Scholar]
  • 266.Lew A., Langford C.J., Pye D., Edwards S., Corcoran L., Anders R.F. Class II restriction in mice to the malaria candidate vaccine ring infected erythrocyte surface antigen (RESA) as synthetic peptides or as expressed in recombinant vaccinia. J. Immunol. 1989;142:4012–4016. [PubMed] [Google Scholar]
  • 267.Meulien P., Faure T., Mischler F., Harrer H., Ulrich P., Bouderbala B., Dott K., Sainte M.M., Mazurier C., Wiesel M.L. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng. 1988;2:301–306. doi: 10.1093/protein/2.4.301. [DOI] [PubMed] [Google Scholar]
  • 268.Citarella F., Aiuti A., La P.C., Russo G., Pietropaolo C., Rinaldi M., Fantoni A. Control of human coagulation by recombinant serine proteases. Blood clotting is activated by recombinant factor XII deleted of five regulatory domains. Eur. J. Biochem. 1992;208:23–30. doi: 10.1111/j.1432-1033.1992.tb17155.x. [DOI] [PubMed] [Google Scholar]
  • 269.Meulien P., Balland A., Lepage P., Mischler F., Dott K., Hauss C., Grandgeorge M., Lecocq J.P. Increased biological activity of a recombinant factor IX variant carrying alanine at position +1. Protein Eng. 1990;3:629–633. doi: 10.1093/protein/3.7.629. [DOI] [PubMed] [Google Scholar]
  • 270.Meulien P., Nishino M., Mazurier C., Dott K., Pietu G., Jorieux S., Pavirani A., Girma J.P., Oufkir D., Courtney M. Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector. Thromb. Haemost. 1992;67:154–160. [PubMed] [Google Scholar]
  • 271.Giavedoni L.D., Jones L., Gardner M.B., Gibson H.L., Ng C.T., Barr P.J., Yilma T. Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc. Natl. Acad. Sci. U.S.A. 1992;89:3409–3413. doi: 10.1073/pnas.89.8.3409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 272.Carroll A.R., Rowlands D.J., Clarke B.E. Synthesis and secretion of a functional antibody in a vaccinia virus expression system. Mol. Immunol. 1992;29:821. doi: 10.1016/0161-5890(92)90119-i. 227. [DOI] [PubMed] [Google Scholar]
  • 273.Estin C.D., Stevenson U.S., Plowman G.D., Hu S.L., Sridhar P., Hellstrom I., Brown J.P., Hellstrom K.E. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 1988;85:1052–1056. doi: 10.1073/pnas.85.4.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 274.Estin C.D., Stevenson U.S., Hellstrom I., Hellstrom K.E. Cyclophospamide potentiates the antitumor activity of v-p97NY. Cell Immunol. 1989;120:126–131. doi: 10.1016/0008-8749(89)90180-9. [DOI] [PubMed] [Google Scholar]
  • 275.Hu S.L., Plowman G.D., Sridhar P., Stevenson U.S., Brown J.P., Estin C.D. Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J. Virol. 1988;62:176–180. doi: 10.1128/jvi.62.1.176-180.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 276.Shepard B., Panicali D., Huang C. Transient expression system to measure the efficiency of vaccinia promoter regions. Plasmid. 1987;18:16–23. doi: 10.1016/0147-619x(87)90074-6. [DOI] [PubMed] [Google Scholar]
  • 277.Cochran M.A., Mackett M., Moss B. Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 1985;82:19–23. doi: 10.1073/pnas.82.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 278.Fridman R., Fuerst T.R., Bird R.E., Hoyhtya M., Oelkuct M., Kraus S., Komarek D., Liotta L.A., Berman M.L., Stetler S.W. Domain structure of human 72 kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J. Biol. Chem. 1992;267:15398–15405. [PubMed] [Google Scholar]
  • 279.Fridman R., Bird R.E., Hoyhtya H., Oelkuct M., Komarek D., Liang C.L., Berman M.L., Liotta L.A., Stetler S.W., Fuerst T.R. Expression of human recombinant 72 kDa gelatinase and issue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem J. 1993;106 doi: 10.1042/bj2890411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 280.Park D., Jhon D.Y., Kriz R., Knopf J., Rhee S.G. Cloning, sequencing, expression, and Gq-independent activation of phospholipase C-beta 2. J. Biol. Chem. 1992;267:16048–16055. [PubMed] [Google Scholar]
  • 281.Seilhamer J.J., Pruzanski W., Vadas P., Plant S., Miller J.A., Kloss J., Johnson L.K. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. 1989;264:5335–5338. [PubMed] [Google Scholar]
  • 282.Agarwal A.K., Tusie L.M., Monder C., White P.C. Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol. Endocrinol. 1990;4:1827–1832. doi: 10.1210/mend-4-12-1827. [DOI] [PubMed] [Google Scholar]
  • 283.Lewis E.J., Allison S., Fader D., Claflin V., Baizer L. Bovine dopamine beta-hydroxylase cDNA. Complete coding sequence and expression in mammalian cells with vaccinia virus vector. J. Biol. Chem. 1990;265:1021–1028. [PubMed] [Google Scholar]
  • 284.Jonjic S., del V.M., Keil G.M., Reddehase M.J., Koszinowski U.H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J. Virol. 1988;62:1653–1658. doi: 10.1128/jvi.62.5.1653-1658.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 285.Del V.M., Schlicht H.J., Volkmer H., Messerle M., Reddehase M.J., Koszinowski U.H. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 1991;65:3641–3646. doi: 10.1128/jvi.65.7.3641-3646.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 286.Stamatos N.M., Chakrabarti S., Moss B., Hare J.D. Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework. J. Virol. 1987;61:516–525. doi: 10.1128/jvi.61.2.516-525.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 287.Gatei M.H., Naif H.M., Kumar S., Boyle D.B., Daniel R.C., Good M.F., Lavin M.F. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51–70. J. Virol. 1993;67:1803–1810. doi: 10.1128/jvi.67.4.1803-1810.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 288.Iacono C.L., Welkos S.L., Ivins B.E., Dalrymple J.M. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immunol. 1991;59:1961–1965. doi: 10.1128/iai.59.6.1961-1965.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 289.Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology. 1991;180:294–305. doi: 10.1016/0042-6822(91)90034-9. [DOI] [PubMed] [Google Scholar]
  • 290.Xu X., Ruo S.L., McCormick J.B., Fisher H.S. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am. J. Trop. Med. Hyg. 1992;47:397–404. doi: 10.4269/ajtmh.1992.47.397. [DOI] [PubMed] [Google Scholar]
  • 291.Pincus S., Mason P.W., Konishi E., Fonseca B.A., Shope R.E., Rice C.M., Paoletti E. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology. 1992;187:290–297. doi: 10.1016/0042-6822(92)90317-i. [DOI] [PubMed] [Google Scholar]
  • 292.Whitton J.L., Sheng N., Oldstone M.B., McKee T.A. A “string-of-beads” vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 1993;67:348–352. doi: 10.1128/jvi.67.1.348-352.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 293.Vennema H., de G.R., Harbour D.A., Dalderup M., Gruffydd J.T., Horzinek M.C., Spaan W.J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 1990;64:1407–1409. doi: 10.1128/jvi.64.3.1407-1409.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 294.Mackett M., Yilma T., Rose J.K., Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985;227:433–435. doi: 10.1126/science.2981435. [DOI] [PubMed] [Google Scholar]
  • 295.Kieny M.P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J.P. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984;312:163–166. doi: 10.1038/312163a0. [DOI] [PubMed] [Google Scholar]
  • 296.Hanlon C.L., Hayes D.E., Hamir A.N., Snyder D.E., Jenkins S., Hable C.P., Rupprecht C.E. Proposed field evaluation of a rabies recombinant vaccine for raccoons (Procyon lotor): site selection, target species characteristics, and placebo baiting trials. J. Wildl. Dis. 1989;25:555–567. doi: 10.7589/0090-3558-25.4.555. [DOI] [PubMed] [Google Scholar]
  • 297.Letellier C., Burny A., Meulemans G. Construction of a pigeonpox virus recombinant: expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch. Virol. 1991;118:43–56. doi: 10.1007/BF01311302. [DOI] [PubMed] [Google Scholar]
  • 298.Moss B., Smith G.L., Gerin J.L., Purcell R.H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984;311:67–69. doi: 10.1038/311067a0. [DOI] [PubMed] [Google Scholar]
  • 299.Spriggs M.K., Collins P.L., Tierney E., London W.T., Murphy B.R. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J. Virol. 1988;62:1293–1296. doi: 10.1128/jvi.62.4.1293-1296.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 300.Deubel V., Kinney R.M., Esposito J.J., Cropp C.B., Vorndam A.V., Monath T.P., Trent D.W. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J. Gen. Virol. 1988;69:1921–1929. doi: 10.1099/0022-1317-69-8-1921. [DOI] [PubMed] [Google Scholar]
  • 301.Brody B.A., Hunter E., Kluge J.D., Lasarow R., Gardner M., Marx P.A. Protein of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3) J. Virol. 1992;66:3950–3954. doi: 10.1128/jvi.66.6.3950-3954.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 302.Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine. 1990;8:164–168. doi: 10.1016/0264-410x(90)90141-8. [DOI] [PubMed] [Google Scholar]
  • 303.Fisher H.S., McCormick J.B., Auperin A., Brown B.G., Castor M., Perez G., Ruo S., Conaty A., Brammer L., Bauer S. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl. Acad. Sci. U.S.A. 1989;86:317–321. doi: 10.1073/pnas.86.1.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 304.Olmsted R.A., Buller R.M., Collins P.L., London W.T., Beeler J.A., Prince G.A., Chanock R.M., Murphy B.R. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine. 1988;6:519–524. doi: 10.1016/0264-410x(88)90104-1. [DOI] [PubMed] [Google Scholar]
  • 305.Zarling J.M., Eichberg J.W., Moran P.A., McClure J., Sridhar P., Hu S.L. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J. Immunol. 1987;139:988–990. [PubMed] [Google Scholar]
  • 306.Zarling J.M., Morton W., Moran P.A., McClure J., Kosowski S.G., Hu S.L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature. 1986;323:344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]
  • 307.Ruby J., Brinkman C., Jones S., Ramshaw I. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Immunol. Cell Biol. 1990;68:113–117. doi: 10.1038/icb.1990.16. [DOI] [PubMed] [Google Scholar]
  • 308.Rupprecht C.E., Hanlon C.A., Cummins L.B., Koprowski H. Primate responses to a vaccinia-rabies glycoprotein recombinant virus vaccine. Vaccine. 1992;10:368–374. doi: 10.1016/0264-410x(92)90065-r. [DOI] [PubMed] [Google Scholar]
  • 309.Hu S.L., Zarling J.M., Chinn J., Travis B.M., Moran P.A., Sias J., Kuller L., Morton W.R., Heidecker G., Benveniste R.E. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc. Natl. Acad. Sci. U.S.A. 1989;86:7213–7217. doi: 10.1073/pnas.86.18.7213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 310.Giavedoni L.D., Planelles V., Haigwood N.L., Ahmad S., Kluge J.D., Marthas M.L., Gardner M.B., Luciw P.A., Yilma T.D. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. Virol. 1993;67:577–583. doi: 10.1128/jvi.67.1.577-583.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 311.Kempe C.H., Fulginiti V., Minimitani M., Shienfield H. Smallpox vaccination of eczma patients with a strain of attenuated live vaccinia (CV-178) Pediatrics. 1968;42:980–985. [PubMed] [Google Scholar]
  • 312.Shuyan, G., Tianmin, H., Yihong, M., Li, R., Yuhe, Z., Chunhui, H., Yao, X., Jiming, Z., and Wolf, H. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin. Med. Sci. J.6, 241–243. [PubMed]
  • 313.Bayliss C.D., Peters R.W., Cook J.K., Reece R.L., Howes K., Binns M.M., Boursnell M.E. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus. Arch. Virol. 1991;120:193–205. doi: 10.1007/BF01310475. [DOI] [PubMed] [Google Scholar]
  • 314.Beard C.W., Schnitzlein W.M., Tripathy D.N. Protection of chickens against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses. Avian Dis. 1992;35:356–359. [PubMed] [Google Scholar]
  • 315.Beard C.W., Schnitzlein W.M., Tripathy D.N. Effect of route of administration on the efficacy of a recombinant fowlpox virus against H5N2 avian influenza. Avian Dis. 1992;36:1052–1055. [PubMed] [Google Scholar]
  • 316.Taylor J., Weinberg R., Kawaoka Y., Webster R.G., Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine. 1991;9:303–308. doi: 10.1016/0264-410x(88)90101-6. [DOI] [PubMed] [Google Scholar]
  • 317.Boursnell M.E., Green P.F., Samson A.C., Campbell J.I., Deuter A., Peters R.W., Millar N.S., Emmerson P.T., Binns M.M. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology. 1990;178:297–300. doi: 10.1016/0042-6822(90)90408-j. [DOI] [PubMed] [Google Scholar]
  • 318.Edbauer C., Weinberg R., Taylor J., Rey S.A., Bouquet J.F., Desmettre P., Paoletti E. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene. Virology. 1990;179:901–904. doi: 10.1016/0042-6822(90)90165-n. [DOI] [PubMed] [Google Scholar]
  • 319.Iritani Y., Aoyama S., Takigami S., Hayashi Y., Ogawa R., Yanagida N., Saeki S., Kamogawa K. Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV. Avian Dis. 1991;35:659–661. [PubMed] [Google Scholar]
  • 320.Boursnell M.E., Green P.F., Campbell J.I., Deuter A., Peters R.W., Tomley F.M., Samson A.C., Emmerson P.T., Binns M.M. A fowlpox virus vaccine vector with insertion sites in the terminal repeats: demonstration of its efficacy using the fusion gene of Newcastle disease virus. Vet. Microbiol. 1990;23:305–316. doi: 10.1016/0378-1135(90)90161-n. [DOI] [PubMed] [Google Scholar]
  • 321.Boursnell M.E., Green P.F., Campbell J.I., Deuter A., Peters R.W., Tomley F.M., Samson A.C., Chambers P., Emmerson P.T., Binns M.M. Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant. J. Gen. Virol. 1990;71:621–628. doi: 10.1099/0022-1317-71-3-621. [DOI] [PubMed] [Google Scholar]
  • 322.Taylor J., Edbauer C., Rey S.A., Bouquet J.F., Norton E., Goebel S., Desmettre P., Paoletti E. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J. Virol. 1990;64:1441–1450. doi: 10.1128/jvi.64.4.1441-1450.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 323.Nazerian K., Lee L.F., Yanagida N., Ogawa R. Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus. J. Virol. 1992;66:1409–1413. doi: 10.1128/jvi.66.3.1409-1413.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 324.Yanagida N., Ogawa R., Li Y., Lee L.F., Nazerian K. Recombinant fowlpox viruses expressing the glycoprotein B homolog and the pp38 gene of Marek's disease virus. J. Virol. 1992;66:1402–1408. doi: 10.1128/jvi.66.3.1402-1408.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 325.Wild F., Giraudon P., Spehner D., Drillien R., Lecocq J.P. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine. 1990;8:441–442. doi: 10.1016/0264-410x(90)90243-f. [DOI] [PubMed] [Google Scholar]
  • 326.Calvert J.G., Nazerian K., Witter R.L., Yanagida N. Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens. J. Virol. 1993;67:3069–3076. doi: 10.1128/jvi.67.6.3069-3076.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 327.Hu S.L., Abrams K., Barber G.N., Moran P., Zarling J.M., Langlois A.J., Kuller L., Morton W.R., Benveniste R.E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992;255:456–459. doi: 10.1126/science.1531159. [DOI] [PubMed] [Google Scholar]
  • 328.Haffar O.K., Smithgall M.D., Moran P.A., Travis B.M., Zarling J.M., Hu S.L. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology. 1991;183:487–495. doi: 10.1016/0042-6822(91)90978-k. [DOI] [PubMed] [Google Scholar]
  • 329.Issacs S.N., Kotwal G.J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U.S.A. 1992;89:628–632. doi: 10.1073/pnas.89.2.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 330.Lettelier C., Burny A., Meulemans G. Construction of a pigeonpox virus recombinant: expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch. Virol. 1991;118:43–56. doi: 10.1007/BF01311302. [DOI] [PubMed] [Google Scholar]
  • 331.Tartaglia J., Jarrett O., Neil J.C., Desmettre P., Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox recombinant, ALVAC-FL. J. Virol. 1993;67:2370–2375. doi: 10.1128/jvi.67.4.2370-2375.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 332.Taylor J., Weinberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Appel M., Norton E., Paoletti E. Non-replicating vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and haemagylutinin (HA) glycoproteins. Virology. 1992;187:321–328. doi: 10.1016/0042-6822(92)90321-f. [DOI] [PubMed] [Google Scholar]

Articles from Animal Cell Biotechnology are provided here courtesy of Elsevier

RESOURCES